At the 2026 NCCN Annual Conference, global oncology discussions emphasized the intersection of social determinants of health ...
Updated interim findings from a phase 1/2 study evaluating ozekibart (INBRX-109) in combination with FOLFIRI demonstrate ...
Results from the phase 3 LITESPARK-012 trial (NCT04736706) demonstrate that intensifying an established first-line regimen ...
EV-304 trial. The U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental biologics license application for enfortumab vedotin-ejfv (Padcev) in combination with ...
Anjali Albanese spoke about the unique emotional and psychosocial challenges faced by younger adults following a cancer ...
New real-world data from the 1INSPIRE study shows that frontline niraparib (Zejula) maintenance is well-tolerated in patients ...
Alembic Pharmaceuticals Limited has received final approval from the U.S. Food and Drug Administration (FDA) for its ...
Because the immune system resides beneath the skin's barrier, the initial cellular mutation caused by UV light occurs before ...
Mirvetuximab soravtansine shows 16.4-month OS in ovarian cancer, though poor ECOG status and toxicity significantly impact ...
Dr. Don Dizon discusses why early fertility referral and avoiding clinical assumptions are vital for young breast cancer patients at diagnosis. According to Dizon, the discussion regarding fertility ...
Dr. Don Dizon discusses why early fertility referral and avoiding clinical assumptions are vital for young breast cancer patients at diagnosis.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results